Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | ACACA | Q13085 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 4/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211997 | 0.86 | MAPT (0.44) | KDM4EALDH1A1ACACBACACACA12 | |
| SCHEMBL15131311 | 0.82 | CHEK1 (0.47) | KDM4EALDH1A1ACACBACACACA1 | |
| SCHEMBL898364 | 0.81 | ACACA (0.42) | KDM4EALDH1A1ACACBACACACA12 | |
| SCHEMBL732334 | 0.81 | CTRC (0.56) | KDM4EALDH1A1CTRCMCL1NPC1 | |
| SCHEMBL18019283 | 0.80 | CHEK1 (0.50) | KDM4EALDH1A1ACACBACACACA1 | |
| SCHEMBL21172189 | 0.76 | ACACB (0.47) | KDM4EALDH1A1ACACBACACACA1 | |
| SCHEMBL20257061 | 0.76 | CHEK1 (0.47) | KDM4EALDH1A1ACACBACACACHEK1 | |
| SCHEMBL10212523 | 0.75 | CHEK1 (0.46) | KDM4EALDH1A1ACACBACACACA1 | |
| SCHEMBL18767236 | 0.75 | KDM4E (0.56) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL527251 | 0.73 | CA1 (0.54) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12472180-B2 | Combinations for treatment of NAFLD/NASH and related diseases | PFIZER INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20150011470-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8859577-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859577-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859577-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2621493-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012042433-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012042433-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | KDM4E 2670/4885ALDH1A1 159/4885ACACB 2/4885 |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, ACACB, PC | KDM4E 1995/4885ALDH1A1 82/4885ACACB 2/4885 |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | KDM4E 1580/4885ALDH1A1 399/4885ACACB 38/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | KDM4E 1577/4885ALDH1A1 348/4885ACACB 2/4885 |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | FABP1, GOT2, CPT1A | KDM4E 1599/4885ALDH1A1 324/4885ACACB 33/4885 |
| US-12472180-B2 | Combinations for treatment of NAFLD/NASH and related diseases | FABP1, GOT2, CPT1A | KDM4E 1599/4885ALDH1A1 324/4885ACACB 33/4885 |
| US-20150011470-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | KDM4E 1995/4885ALDH1A1 82/4885ACACB 2/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | KDM4E 899/4885ALDH1A1 743/4885ACACB 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.